PRIMARY STUDY
Endocannabinoids and Schizophrenia
Key Findings: Pre-clinical studies strongly suggest that ECBs play a role in neurogenesis, neurodegenerative processes, as well as in the neural circuits thought to be impaired in schizophrenia. In humans, mounting evidence shows that CB1 receptor densities are altered in schizophrenia and that anandamide levels are elevated, suggesting that the ECBs are involved in the pathophysiology of the disorder.
Type of Study: Meta-analysis
Study Result: Inconclusive
Research Location(s): Canada
Year of Pub: 2010
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, PPAR - Gamma, PPARs
Ligands Studied: Acetylcholine, GABA, Glutamate, Norepinephrine
Citation:
